Full name
A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy (OCEAN)
NCT Number
NCT05263934
Geography
US
Non-US
Locations
Argentina, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, Israel, Italy, Japan, Republic of Korea, Netherlands, Poland, Portugal, Spain, Sweden, United Kingdom, United States
Primary Endpoints
Number of participants with remission (Birmingham Vasculitis Activity Score [BVAS] =0 and a dose of oral corticosteroid [OCS] less than or equal to [<] 4 milligram [mg] per day). Up to Week 52
External Link
https://clinicaltrials.gov/study/NCT05263934
Order
1
Disease
Version
Phase
3
Status
Recruiting